tuneTypical Dose
250-1000 mcg per day for prevention, or 1000-2000 mcg per day (deficiency correction)
Vitamin
Vitamin B12
Cobalamin (cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin)
Evidence TierAWADA NOT PROHIBITED
watchEffect Window
Days to weeks for anemia correction. Months for neurological recovery.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Vitamin B12 is required for red blood cell formation, DNA synthesis, and myelin maintenance. It is used to correct deficiency, especially in vegans, older adults, and malabsorption states.
Correcting deficiency resolves megaloblastic anemia and can improve fatigue, cognitive symptoms, and neuropathy. Benefits are particularly relevant in vegan diets, older age with reduced absorption, and with metformin or acid suppression use. A 2025 meta-analysis also reinforces that oral and sublingual replacement are usually as effective as intramuscular therapy for raising B12 status in deficiency care. Minority evidence suggests improvements in sleep-wake complaints and fertility biomarkers in deficient individuals. Once adequacy is achieved, additional intake provides little extra benefit.
Coenzyme for methionine synthase (homocysteine to methionine) and L-methylmalonyl-CoA mutase. Essential for DNA synthesis, myelin maintenance, and red blood cell maturation.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Corrects megaloblastic anemia in B12-deficient populations
- Reverses peripheral neuropathy from B12 deficiency
- Lowers homocysteine (with folate and B6)
Secondary Outcomes
- Slows brain atrophy in B12-deficient elderly with elevated homocysteine
- No cognitive or cardiovascular benefit in replete individuals
Safety
Contraindications and Interactions
Contraindications
- Leber's hereditary optic neuropathy (cyanocobalamin form)
Side effects
- None at standard oral doses with no established UL.
- Mild gastrointestinal symptoms (nausea, diarrhea, abdominal pain), usually at higher doses.
- Headache (typically mild).
- Rare acneiform eruptions at very high doses (>5000 mcg).
- Rare hypersensitivity/allergic reactions to cobalamin formulations.
- Rare hypokalemia when treating severe megaloblastic anemia, especially after parenteral initiation.
Interactions
- Metformin (reduces absorption)
- PPIs/H2 blockers (reduce absorption)
- Colchicine (reduces absorption)
Avoid if
- Leber's hereditary optic neuropathy (cyanocobalamin specifically)
Evidence
Study-level References
vitamin-b12-SRC-001Systematic Review of RCTs
Sourceopen_in_newVidal-Alaball J, et al. "Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency." Cochrane Database Syst Rev. 2005.
Population: Adults with B12 deficiency
Dose protocol: 1000-2000 mcg oral daily vs IM injections
Key findings: High oral doses of B12 (1000-2000 mcg) were as effective as intramuscular administration in achieving hematological and neurological responses.
Paper content
High oral doses of B12 (1000-2000 mcg) were as effective as intramuscular administration in achieving hematological and neurological responses.
vitamin-b12-SRC-001ASystematic review and meta-analysis
Sourceopen_in_newMazur M, Ndokaj A, Salerno C, Vallone J, Ardan R, Bietolini S, Carrouel F, Wilk A, Sarig R, Ottolenghi L, Bourgeois D. Efficacy of sublingual and oral vitamin B12 versus intramuscular administration: insights from a systematic review and meta-analysis. Front Pharmacol. 2025;16:1602976. doi:10.3389/fphar.2025.1602976. PMID:41487531.
Population: Participants with vitamin B12 deficiency or low B12 status across randomized and observational studies.
Dose protocol: Oral, sublingual, and intramuscular vitamin B12 regimens pooled across 16 studies
Key findings: The 2025 meta-analysis found meaningful improvement in serum cobalamin and homocysteine with no significant efficacy difference between oral, sublingual, and intramuscular routes.
Notes: This modernizes the route-of-administration claim and supports oral replacement as the practical default for most deficiency settings.
Paper content
A 2025 meta-analysis found that vitamin B12 supplementation meaningfully raises serum cobalamin and lowers homocysteine across oral, sublingual, and intramuscular routes, with no significant difference between routes. The findings reinforce that high-dose oral or sublingual replacement is a practical alternative to intramuscular treatment for most deficiency states.
vitamin-b12-SRC-002RCT (n=5522)
Sourceopen_in_newLonn E, et al. "Homocysteine lowering with folic acid and B vitamins in vascular disease." NEJM. 2006 (HOPE-2 trial).
Population: Adults with vascular disease or diabetes
Dose protocol: Folic acid 2.5 mg + B6 50 mg + B12 1 mg daily for 5 years
Key findings: Homocysteine reduced by 25%, but no significant reduction in cardiovascular death, MI, or stroke. Modest stroke reduction in post-hoc analysis.
Paper content
Homocysteine reduced by 25%, but no significant reduction in cardiovascular death, MI, or stroke. Modest stroke reduction in post-hoc analysis.
vitamin-b12-SRC-003RCT (n=3680)
Sourceopen_in_newToole JF, et al. "Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death." JAMA. 2004 (VISP trial).
Population: Adults with recent ischemic stroke
Dose protocol: High-dose B vitamins (B12 + B6 + folate) vs low-dose for 2 years
Key findings: No benefit of high-dose B vitamin supplementation on recurrent stroke, MI, or death despite homocysteine reduction.
Paper content
No benefit of high-dose B vitamin supplementation on recurrent stroke, MI, or death despite homocysteine reduction.
vitamin-b12-SRC-004RCT (n=168)
Sourceopen_in_newSmith AD, et al. "Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial." PLoS ONE. 2010 (VITACOG trial).
Population: Elderly with mild cognitive impairment
Dose protocol: B12 500 mcg + folate 800 mcg + B6 20 mg daily for 2 years
Key findings: B vitamin treatment slowed brain atrophy by 30% overall and up to 53% in participants with elevated homocysteine. Benefit was concentrated in those with low baseline B12.
Paper content
B vitamin treatment slowed brain atrophy by 30% overall and up to 53% in participants with elevated homocysteine. Benefit was concentrated in those with low baseline B12.
vitamin-b12-SRC-005Open-label extension of a multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial.
Sourceopen_in_newKaji R, Nishi Y, Ishida T, et al. Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study. J Neurol Sci. 2026;480:125701. doi:10.1016/j.jns.2025.125701. PMID:41475066.
Population: Patients with advanced ALS (mean disease duration 53.2 months).
Dose protocol: Methylcobalamin 50 mg IM twice weekly for up to 52 weeks in ALS patients
Key findings: Ultra-high-dose methylcobalamin was well tolerated with adverse drug reactions in only 3.5% of patients. Survival was 85.7% at 52 weeks.
Notes: Establishes long-term safety at extreme doses far above typical supplementation. ALS is not a standard B12 indication.
Paper content
This open-label extension study evaluated the long-term safety of ultra-high-dose methylcobalamin (50 mg IM twice weekly) in 144 ALS patients over 52 weeks. Adverse drug reactions occurred in only 3.5% of patients, mainly mild proteinuria. Survival was 85.7% at 52 weeks, and functional decline was modest (median ALSFRS change of -1.0). The study established that ultra-high-dose methylcobalamin has an acceptable safety profile in a severely ill population, though it was not designed to assess efficacy in this extension phase. While ALS is not a typical B12 supplementation indication, the safety data at these extreme doses provides useful boundary information for B12 tolerability.
vitamin-b12-SRC-006Randomized controlled trial.
Sourceopen_in_newSalem MS, Hamdy NA, Elghoneimy HA, El Gowelli HM. Efficacy of L-methylfolate and methylcobalamin in treating resistant hypertension associated with elevated serum homocysteine in hemodialysis patients. BMC Nephrol. 2026;27(1):123. doi:10.1186/s12882-025-04726-8. PMID:41580678.
Population: End-stage renal disease patients with resistant hypertension on hemodialysis.
Dose protocol: L-methylfolate 800 mcg + methylcobalamin 1,000 mcg daily for 3 months in hemodialysis patients
Key findings: Treatment group showed significantly lower blood pressure and reduced homocysteine (P=0.006 between groups).
Notes: Small sample (n=51), unblinded, combination product. Supports B12 plus folate for homocysteine reduction in renal populations.
Paper content
This RCT tested daily L-methylfolate (800 mcg) plus methylcobalamin (1,000 mcg) for 3 months in 51 hemodialysis patients with resistant hypertension and elevated homocysteine. The treatment group showed significantly lower pre- and post-dialysis blood pressure and reduced serum homocysteine compared to controls (P=0.006). The study supports the homocysteine-lowering effect of B12 plus folate in a renal population and suggests this may have clinical relevance for blood pressure management in hemodialysis, though the small sample size and lack of blinding are limitations. The methylcobalamin dose (1,000 mcg/day) aligns with typical deficiency correction dosing.
vitamin-b12-SRC-007Multicenter randomized clinical trial.
Sourceopen_in_newReyes-Alvarez MT, Chavez Minano V, Garro-Barrera B, et al. Hydroxocobalamin, thiamine, and pyridoxine as an adjunct to standard treatment in chronic low back pain: a randomized clinical trial. Med Clin (Barc). 2026. doi:10.1016/j.medcli.2025.107307. PMID:41604864.
Population: Patients with chronic mechanical low back pain across six Peruvian centers.
Dose protocol: Injectable B vitamins (hydroxocobalamin, thiamine, pyridoxine) plus NSAIDs in chronic low back pain
Key findings: 84% of B-vitamin group achieved 30% or greater pain reduction versus 64% in controls (RR 1.31, P=0.007).
Notes: Combination product. Cannot isolate B12 contribution. Supports B vitamin adjunct use for chronic pain.
Paper content
This multicenter randomized trial across six Peruvian centers tested injectable B vitamins (B12, B1, and B6) as an adjunct to standard NSAID treatment in chronic mechanical low back pain. The B-vitamin group had a significantly higher responder rate, with 84% achieving at least 30% pain reduction compared to 64% in the NSAID-only group. This supports the long-standing use of combined B vitamins for neuropathic and musculoskeletal pain, with pyridoxine (B6) contributing to the combination through its role in neurotransmitter synthesis and nerve function. The injectable route and combination formulation make it difficult to isolate the specific contribution of B6 alone.